BACKGROUND: Technical advances in radiation oncology provide new opportunities to study neurobehavioral outcomes of radiation therapy (RT) in children treated for brain tumors. METHODS: In this study, we describe an approach to modeling late-effects using integral biologically effective dose (IBED) combined with improved measurement of critical neuropsychological functions. RESULTS: IBED was found to provide more differentiated information about dose distribution than prescribed dose in five subjects treated for brain tumors. Furthermore, IBED was more closely related than was prescribed dose to specific changes in Attention 2-3 years post-RT. CONCLUSIONS: Results support the feasibility of this methodology as well as promising preliminary evidence of the relationship of IBED to the construct of Attention. Improved modeling could lead to more refined radiation therapy protocols that preserve critical neuropsychological functions and also provide new insights into the treatment of neurobehavioral sequelae.
BACKGROUND: Technical advances in radiation oncology provide new opportunities to study neurobehavioral outcomes of radiation therapy (RT) in children treated for brain tumors. METHODS: In this study, we describe an approach to modeling late-effects using integral biologically effective dose (IBED) combined with improved measurement of critical neuropsychological functions. RESULTS: IBED was found to provide more differentiated information about dose distribution than prescribed dose in five subjects treated for brain tumors. Furthermore, IBED was more closely related than was prescribed dose to specific changes in Attention 2-3 years post-RT. CONCLUSIONS: Results support the feasibility of this methodology as well as promising preliminary evidence of the relationship of IBED to the construct of Attention. Improved modeling could lead to more refined radiation therapy protocols that preserve critical neuropsychological functions and also provide new insights into the treatment of neurobehavioral sequelae.
Authors: Kimberly P Raghubar; Michael Lamba; Kim M Cecil; Keith Owen Yeates; E Mark Mahone; Christina Limke; David Grosshans; Travis J Beckwith; M Douglas Ris Journal: Pediatr Blood Cancer Date: 2018-06-01 Impact factor: 3.167
Authors: Adam T Schmidt; Rebecca B Martin; Arzu Ozturk; Wendy R Kates; Moody D Wharam; E Mark Mahone; Alena Horska Journal: Neurocase Date: 2010-02 Impact factor: 0.881
Authors: Traci W Olivier; Johnnie K Bass; Jason M Ashford; Rebecca Beaulieu; Sarah M Scott; Jane E Schreiber; Shawna Palmer; Donald J Mabbott; Michelle A Swain; Melanie Bonner; Robyn Boyle; Mary Lynn Chapeiski; Karen D Evankovich; Carol L Armstrong; Sarah J Knight; Shengjie Wu; Arzu Onar-Thomas; Amar Gajjar; Heather M Conklin Journal: J Clin Oncol Date: 2019-05-02 Impact factor: 44.544
Authors: Lisa S Kahalley; M Douglas Ris; Anita Mahajan; M Fatih Okcu; Murali Chintagumpala; Arnold C Paulino; William E Whitehead; Charles G Minard; Heather H Stancel; Jessica Orobio; Judy J Xue; Emily A Warren; David R Grosshans Journal: Neuro Oncol Date: 2019-06-10 Impact factor: 12.300